- Home
- NLY vs INCY Comparison
NLY vs INCY Comparison
Compare NLY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NLY | INCY |
|---|---|---|
| Founded | 1996 | 1991 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.0B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | NLY | INCY |
|---|---|---|
| Price | $21.13 | $94.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $23.73 | ★ $102.00 |
| AVG Volume (30 Days) | ★ 7.9M | 1.4M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 6.41 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $188.83 | $10.97 |
| Revenue Next Year | $2.40 | $10.48 |
| P/E Ratio | ★ $7.88 | $14.72 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $16.60 | $53.56 |
| 52 Week High | $24.52 | $112.29 |
Technical Indicators
Market Signals| Indicator | NLY | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.16 | 49.04 |
| Support Level | $20.43 | $93.54 |
| Resistance Level | $21.16 | $108.79 |
| Average True Range (ATR) | 0.48 | 2.37 |
| MACD | -0.03 | 0.43 |
| Stochastic Oscillator | 28.37 | 80.89 |
Price Performance
Historical ComparisonAbout NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.